EBOS is probably a name many Australians haven’t heard before. However, it’s a $1.2 billion New Zealand pharmaceutical retailer which occupies leading positions across a number of industry sub groups. It has made approximately 20 acquisitions in the past 12 years and achieved a total shareholder return (dividends plus capital gains) of 19% per year, over the past decade. In 2013, EBOS acquired Symbion for $1.1 billion and has stated the integration of the business has been largely successful. Interestingly, the acquisition provided a foothold in the pet care market, where the group will continue to grow in years ahead.
Indeed, in coming years, analysts are forecasting strong earnings per share growth. I’m cautiously optimistic about the company’s future, but I’m not a buyer today. Other than the lack of liquidity in the Australian-listed shares, I’d like to see how the company fares in the coming 24 months before committing to a purchase.
She will find out in due course.!!!! lol.
You would laugh at me this morning,running around like a chook with its head chopped off.
My wife heard the talk on the radio and told me EBO had made a $300mil acquisition.Looked at EBO site,NZX site,Stocknessmonster site,the Herald site,the age site and could not find anything..!!!
So thanks Noodles for posting the link and getting me up to speed.!!!
I'd hope so as EBO is one of my biggest holdings. A note of caution though as Aust grows in importance to the company and the AUD weakens against the NZD.
Originally Posted by noodles
Reply With Quote
Bookmarks